MedTrace Logo

IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

NCT05077709 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2026-04-08

Study results available
· View outcomes & findings →

Summary

A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head or Neck (SCCHN), or Metastatic Urothelial Bladder Cancer (mUBC)

Conditions

Interventions

DRUG

IO102-IO103 in combination with pembrolizumab

The experimental drug IO102-IO103 is for SC injection and consist of IDO and PD-L1 peptides

Sponsors & Collaborators

  • Theradex

    collaborator INDUSTRY

  • Almac

    collaborator INDUSTRY

  • NeoGenomics

    collaborator UNKNOWN

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • IO Biotech

    lead INDUSTRY

Principal Investigators

  • Jonathan W Riess, MD, MSc · Division of Hematology/Oncology, UC Davis Comprehensive Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-11
Primary Completion
2025-11-30
Completion
2026-02-08
FDA Drug
Yes

Countries

  • United States
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05077709 on ClinicalTrials.gov